Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amarin Claims ‘Little Impact’ From Teva’s US Vascepa Generic

Originator Aware Of Potential Fifth Launch From Zydus Cadila

Executive Summary

“They have prescriptions just in the hundreds per week, which is in a market of 100,000 or so prescriptions a week,” Amarin has said of Teva’s Vascepa generic, the fourth to reach the US market.

You may also be interested in...



Zydus Looks To NASH Trials In Turkey, gVascepa Launch In The US

Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter

Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’

Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.

Coherus Delivers First US Rival To Neulasta OnPro, As Biosimilar Interest Peters Out

“Innovating cancer care for patients is a winning strategy,” Coherus said as it delivered on the first US biosimilar version of Amgen’s dominant pegfilgrastim formulation, using an on-body device to deliver the medication, months after a protracted FDA approval.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel